Toll-like receptors (TLRs) shape trained immunity, balancing infection responses and chronic inflammation, and TLR agonists are promising immunomodulators for infectious diseases and cancer.

Engineered bacteria reprogram tumor macrophages and direct copper into cancer cells, triggering cell death and systemic immunity without damaging healthy tissue.

Researchers developed and validated a label-free, non-invasive method combining AFM with deep learning for accurate profiling ...

When the lungs are attacked by a virus, the damage doesn't stop there. The body's natural defenses cause inflammation while ...

Cellular and molecular regulators play a pivotal role in non-neoplastic immune-mediated diseases, where the immune system ...

T-cell exhaustion and pre-existing T-cell immunity in circulation as predictive biomarkers for immunotherapy in NSCLC patients. Monitoring PD-L1 expression in cancer-associated macrophage-like cells ...

New findings reveal how cancer manipulates immune pathways and highlight therapeutic strategies to unleash T-cells against even the most resistant tumors. Study: Cancer cells impair monocyte-mediated ...

The emerging role of SETD2 in regulating immune cell function is shedding light on potential therapeutic strategies for a range of immune-related diseases. As a key methyltransferase, SETD2 ...

Five signaling subtypes identified by NMF clustering. Subtype 5 (high APsig) correlates with immune-rich "hot" tumors, while Subtype 2 (low APsig) exhibits metabolic reprogramming and hypoxia. High ...